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Abstract 
BACKGROUND: Determinant prognostic factors of 28 days survival rate in patients with a first 
acute myocardial infarction (AMI) based on gender in teen year’s period in Isfahan, Iran, was 
the aim of this study. 
METHODS: This study is a prospective hospital-based study that consisted, all patients with AMI 
admitted to all hospitals (private and universal hospitals) in Isfahan and Najafabad (Iran) during 
2000-2009. To determinant the prognostic factors of 28 days survival rate in patients based on 
gender, analysis conducted separately for male and female. In analysis, we use of t-test, log Rank 
tests, Kaplan–Meier method, and univariate and multivariate Cox regression model. 
RESULTS: Short-term (28 days) survival rate was 92.5% in male and 86.7% in female  
(P < 0.001). The adjusted hazard ratio (HR) of death for age group 80 years and older was 12.7 
[95% confidence interval (CI): 5.14-31.3] in male and 8.78 (95% CI: 1.2-63.1) in female. HR for 
acute transmural MI of the unspecified site in male was 8.9 (95% CI: 4.68-16.97) and in female 
9.33 (95% CI: 4.42-19.7). HR for receive of streptokinase in male was 1.11 (95% CI: 0.94-1.31) 
and in female was 0.69 (95% CI: 0.56-0.84). 
CONCLUSION: Short-term survival rate in male was a higher than female. In male age, anatomic 
location of MI and hospital status and in female streptokinase use and anatomic location of MI 
was the most important prognostic factors of survival in-patient with AMI in Isfahan. 
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Introduction 
Cardiovascular disease is one of the first causes of 
death in the world and Iran.1 These diseases have 
increasing trends particularly in low-and moderate-
income countries.2 According to international 
reports, mortality from acute myocardial infarction 
(AMI) have rising trend,3 and coronary artery disease 
(CAD) will remain among the three main causes of 
the global burden of disease to 2030.4 According to 
the first national burden of disease study in Iran, 
CAD was the third factors of disability-adjusted life 
years in all ages and two genders (16% of total 
burden of disease). That led to 1 billion years of life 
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thousand years lived with disability.5 Despite a 
significant reduction in the amount of prevalence of 
coronary heart disease (CHD) in many countries6 and 
advances in the treatment of patients,7 case fatality 
rate (CFR) the following the incidence of AMI in 
both genders has remained high.8 On the other hand, 
death from cardiovascular disease is the primarily 
cause of mortality in Iran.1,9 
Accordingly, identifying predictive factors of 
mortality in patients could be an important role in 
reducing deaths from the disease, partially in 
countries such Iran that scattered reports have about 
the factors affecting the survival of patients with 
AMI. In studies that conducted in different parts of 
the world, factors such as diabetes mellitus, smoking, 
age, sex, hyperlipidemia, hypertension, previous MI 
introduced as the predictor of survival from AMI.10,11 
In this study, in addition the demographic 
variables, we assess the role of type of AMI base on 
International Classification of Diseases version-10 
(ICD-10), cardiac enzymes, symptoms, type of 
hospital, the first referral center for health services and 
streptokinase use as predictor of survival after first 
AMI, which less attention has paid to them in other 
studies. Thus, the aims of this study are determination 
of prognostic factors of 28 days (short-term) survival 
rate in patients with the first AMI based on gender in 
10-year period in Isfahan, Iran. 
Materials and Methods 
This study is a prospective hospital-based study that 
consisted all patients with first AMI during  
2000-2009 in the Isfahan and Najafabad (Iran). At 
the time, the study was performed about 13 
hospitals were admitting and managing CHD 
patients in Isfahan. 
In this registry, all possible CHD events were 
registered with ignoring MONICA age limitation. 
The MONICA MI diagnostic criteria were 
applied.12 Diagnostic criteria are based on a 
collection of standardized information including 
past history of MI or ischemic heart disease, 
symptoms at onset, maximum levels of serum 
enzymes in admitted 1st day in the hospital, and 
relevant electrocardiograms (coded according to the 
Minnesota codes).13 The World Health 
Organization (WHO) MONICA Project is 
concerned with events, not persons. Events are 
classified as first or recurrent.12 In this study, only 
first events are included. 
Hospital intensive care unit (ICU), coronary 
care unit (CCU), and cardiology ward admission 
and discharge lists were used for case finding. 
Records of patients hospitalized in cardiology 
wards, CCUs or in other wards but under 
complete or partial supervision of cardiologists 
were evaluated for possible signs and symptoms of 
CHD events. This evaluation was done by three 
experienced registered nurses trained in this regard 
before the study. They summarized proper records 
in special checklists containing information in age, 
sex, event date and hospitalization date, symptoms, 
history of previous MI, enzymes, admission 
electrocardiogram, whether the event was 
iatrogenic, survival status in discharge and after 28 
days follow-up, and whether thrombolytic were 
used during hospitalization. The filled records 
were checked by an expert nurse with special 
training for the MONICA registration system. 
Moreover, 10% of the checklists was randomly 
chosen and refilled by the expert nurse from the 
original hospital records and compared with ones 
registered nurses had filled to see if any mistakes 
occurred. The patients investigated after admission 
to hospitals and patients with AMI related to 
different event locations assigned a specific code 
according to ICD-10, these codes were I21.0 
(acute transmural MI of anterior wall), I21.1 (acute 
transmural MI of inferior wall), I21.2 (acute 
transmural MI of other sites), I21.3 (acute 
transmural MI of unspecified site), I21.4 (acute 
subendocardial MI) and I21.9 (AMI, unspecified), 
considering categorized AMI.14 
MONICA and the WHO protocol defined AMI 
as a 28 days repeated attack, not considered as 
separate attacks but in fact related to the first AMI; 
however, following the first night of the 27th day 
after the attack it is considered as a new attack. 
Patients who died during the first 28 days are 
considered as death due to first AMI.15 After 
collecting basic information about patients, their 
survival or death during the 28 days after the AMI 
were evaluated. For discharged patients, follow-up 
was the first executed by telephone but when their 
survival rates were not determined after three 
telephone calls, we went to the patients’ homes. 
When previous efforts in terms of getting 
information about survival rate failed, using the 
national organization for civil registration and 
Isfahan cemetery, we tried to find out if the patient 
had died; we found the cause of death and exact 
date and location of the burial.16 A detailed 
description of the methods used in this project was 
provided in previous reports.16-24 
Overall, 14450 patients (10334 men and 4116 
women) with first AMI, that inhabitants in Isfahan 
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and Najafabad entered in the study, 886 patients 
(564 men and 322 women) were excluded because 
their AMI type was not determined according to the 
ICD-10. In addition, 118 patients (82 men and 36 
women) exclude from the study, because died 
during the 28 days after the first attack without 
mention of any cardiovascular disease due to 
accident, suicide, homicide, chronic obstructive 
pulmonary disease (COPD), cancer, liver cirrhosis, 
rheumatic heart disease, vascular disease, or 
atherosclerosis. In addition, 418 patients (292 men 
and 126 women) were excluded because outcome 
was unknown, and 128 patients (89 men and 39 
women) was excluded from the study, Because the 
exact date of the occurrence or death from the 
disease was not specified and the 28 days duration 
after the attack could not be calculated in these 
cases,15 also 85 patient (47 men and 38 women) 
were excluded because symptom or cardiac 
enzymes was not recorded. Therefore, 12815 
patients, 9307 (72.6%) men and 3508 (27.4%) 
women, remained in the study (Tables 1 and 2). 
 
Table 1. Clinical survival predictive factors in male with acute myocardial infarction 








(95% CI) P 
Age in male (year)       
39 year and lower 399 394 5 98.75 R - 
40-49 1629 1587 42 97.42 2.24 (0.88-5.66) 0.091 
50-59 2525 2423 102 95.96 3.48 (1.41-8.55) 0.007 
60-69 2343 2150 193 91.76 7.00 (2.87-17.00) < 0.001 
70-79 1886 1629 257 86.37 10.54 (4.34-25.60) < 0.001 
80 year and older 525 427 98 81.33 12.7 (5.14-31.30) < 0.001 
Streptokinase       
Receiving 5181 4864 317 93.88 R - 
Not receiving 4126 3746 380 90.79 1.11 (0.94-1.31) 0.340 
ICD-10       
Acute subendocardial MI 752 736 16 97.87 R - 
Acute transmural MI of other sites 232 225 7 96.98 1.42 (0.58-3.47) 0.299 
Acute transmural MI of inferior wall 2759 2650 109 96.05 1.74 (1.02-3.00) 0.035 
Acute transmural MI of anterior wall 3187 2974 213 93.32 3.02 (1.78-5.11) < 0.001 
Acute MI, unspecified 2266 1938 328 85.53 5.90 (3.54-9.86) < 0.001 
Acute transmural MI of unspecified site 106 82 24 77.36 8.92 (4.68-16.97) < 0.001 
The first center was referred       
Non-specialized hospitals 638 573 65 89.81 2.11 (1.23-3.75) 0.011 
Specialized hospital 8137 7547 590 92.75 1.50 ( 0.89-2.51) 0.200 
Unknown 235 208 27 88.51 2.17 (1.11-4.00) 0.027 
Health network or clinic 297 282 15 94.95 R - 
Symptoms       
Typical 7773 7250 523 93.27 R - 
A typical 1085 993 92 91.52 1.06 (0.85-1.36) 0.391 
Others 414 339 75 81.88 1.67 (1.29-2.63) < 0.001 
Miss 6 5 1 83.33 1.87 (0.87-4.00) 0.094 
***Cardiac enzymes       
A typical 1087 1026 61 94.39 R - 
Typical 7080 6597 483 93.18 1.27 (0.97-1.67) 0.078 
Others 825 780 45 94.55 0.96 (0.65-1.40) 0.880 
Not clear 315 207 108 65.71 4.81 (3.46-6.67) < 0.001 
Hospital       
Privative hospitals 763 716 47 93.84 R - 
Academic hospitals 8544 7894 650 92.39 1.45 (1.12-1.96) 0.018 
*Survival rates at 28 days after the occurrence of the disease (percent). **Every variable adjusted for other variables. ***LDH (lactate 
dehydrogenase), CPK (creatine phosphokinase) and troponin.  
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Table 2. Clinical survival predictive factors in female with acute myocardial infarction  








(95% CI) P 
Age in female (year)       
39 year and lower 41 40 1 97.56 R - 
40-49 234 224 10 95.73 1.86 (0.23-14.11) 0.553 
50-59 611 569 42 93.13 2.55 (0.35-18.63) 0.318 
60-69 1038 920 118 88.63 4.39 (0.61-31.50) 0.123 
70-79 1152 962 190 83.51 6.01 (0.84-43.00) 0.060 
80 year and older 432 327 105 75.69 8.78 (1.20-63.10) 0.025 
Streptokinase       
Receiving 1483 1260 223 84.96 R  - 
Not receiving 2025 1782 243 88.00 0.69 (0.56-0.84) < 0.001 
ICD-10       
Acute subendocardial MI 438 426 12 97.26 R  - 
Acute transmural MI of other sites 87 78 9 89.66 2.46 (1.02-5.90) 0.043 
Acute transmural MI of inferior wall 901 819 82 90.90 2.27 (1.22-4.12) 0.009 
Acute transmural MI of anterior wall 1069 945 124 88.40 3.09 (1.68-5.67) < 0.001 
Acute MI, unspecified 969 749 220 77.30 6.36 (3.53-11.45) < 0.001 
Acute transmural MI of unspecified site 44 25 19 56.82 13.12 (6.28-27.39) < 0.001 
The first center was referred       
Non-specialized hospitals 238 185 53 77.73 1.65 (0.94-2.90) 0.136 
specialized hospital 3080 2697 383 87.56 0.83 (0.50-1.38) 0.344 
Unknown 80 66 14 82.50 1.25 (0.60-2.61) 0.621 
Health network or clinic 110 94 16 85.45 R  - 
Symptoms       
Typical 2855 2489 366 87.18 R  - 
A typical 408 367 41 89.95 0.83 (0.60-1.16) 0.250 
Others 226 171 55 75.66 1.52 (1.12-2.03) 0.021 
Miss 19 15 4 78.95 1.35 (0.52-3.63) 0.736 
***Cardiac enzymes       
A typical 546 491 55 89.93 R  - 
Typical 2464 2175 289 88.27 1.05 (0.77-1.40) 0.447 
Others 318 281 37 88.36 1.37 (0.90-2.08) 0.186 
Not clear 180 95 85 52.78 4.58 (3.24-6.54) < 0.001 
Hospital       
Privative hospitals 278 246 32 88.49 R  - 
Academic hospitals 3230 2796 434 86.56 1.23 (0.85-1.77) 0.229 
*Survival rates at 28 days after the occurrence of the disease (percent). **Every variable adjusted for other variables. ***LDH (lactate 
dehydrogenase), CPK (creatine phosphokinase) and troponin.  
HR: Hazard ratio; ICD: International classification of disease-10; CI: Confidence interval; MI: Myocardial infarction 
 
Variables that considered in the study include, age 
that divide in six sub-group (39 years and lower, 40-49, 
50-59, 60-69, 70-79, and 80 and older), streptokinase 
use (receiving or not receiving), type of AMI based 
ICD-10, that include six categories (acute 
subendocardial MI, acute transmural MI of other sites, 
acute transmural MI of inferior wall, acute transmural 
MI of anterior wall, AMI, unspecified, acute 
transmural MI of unspecified site), the first center that 
patient referred forget medical care (non-specialized 
hospitals, specialized hospital, unknown, health 
network or clinic), symptoms (typical, A typical, 
others, not clear), cardiac enzymes (A typical, typical, 
others, not clear) and hospital status (privative 
hospitals and academic hospitals). 
In this study, continuous variables are 
presented as mean ± standard deviation (SD). To 
compare average age in two genders, we use of the 
independent t-test. Time-dependent event 
(survival) rates were estimated by Kaplan-Meier 
method and P values were determined by use of 
log-rank statistics. The assumption of proportional 
hazards assessed by graphing the log-minus-log. 
Furthermore, to calculate the hazard ratio (HR) of 
death in 28 days of onset AMI, multivariate Cox 
regression analyses were used for calculation 
adjusted HR and category that have the lowest 
mortality, considered as reference group. In 
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calculate of adjusted HR every variable adjusted 
for other variables. Statistical significance was 
assumed if P < 0.050. All reported P values are 
two-sided. Statistical analyses were performed 
using SPSS software (version 15, SPSS Inc., 
Chicago, IL, USA). 
Results 
In this study, the average age of the patient in the 
time of disease occurrence was (12815 patients)  
61.8 ± 12.6, in male (9307 patients) 60.0 ± 12.5 and 
in female (3508 patients) 66.7 ± 11.3, that this 
different was statically significant (P < 0.001). Sex 
ratio (male/female) was 2.65. Short-term (28 days) 
survival rate in study period was 90.9%, in male 
92.5% and in female 86.7% (P < 0.001). 
In male, the HR of death in the first 28 days 
after the occurrence of MI increased, so in 50-59 
years age group HR was 3.48 [95% confidence 
interval (CI): 1.41-8.55, (P < 0.001) ], in 60-69 
years age group was 7 [95% CI: 2.87-17.00,  
(P < 0.001)], in 70-79 years age group was 10.54 
[95% CI: 4.34-25.60, (P < 0.001)], and in 80 years 
and older was 12.7 [95% CI: 5.14-31.30,  
(P < 0.001)]. HR of death for other variables is 
presented in table 1. 
HR for patients that referred to non-specialized 
hospitals as the first center for getting medical care 
was, 2.11 [95% CI: 1.23-3.75, (P = 0.011)], for 
unknown status was 2.17 [95% CI: 4.68-16.97,  
(P < 0.001)]. For patients with symptom other than 
typical, and A typical was 1.67 [95% CI: 1.29-2.63, 
(P < 0.001)]. In patients with cardiac enzymes 
[creatine phosphokinase (CPK) and lactic 
dehydrogenase] unclear was 4.81 [95% CI:  
3.46-6.67, (P < 0.001)] and for patents in Academic 
hospitals was 1.45 [95% CI: 1.12-1.96, (P = 0.018)]. 
HR of death within 28 days after the occurrence of 
MI for other variable and sub variables in male was 
not statistical significant (Table 1). 
In Female, HR of death in the first 28 days after 
the occurrence of MI were statistical significantly, 
only in 80 years and older age group that was 8.78 
[95% CI: 1.20-63.10, (P = 0.025)]. HR of death for 
other variables is presented in table 2. 
For patients with symptom other than typical, 
and A typical was 1.52 [95% CI: 1.12-2.03,  
(P = 0.021)]. In patients with cardiac enzymes (CPK 
and lactate dehydrogenase (LDH)] unclear was 4.58 
[95% CI: 3.24-6.54, (P < 0.001)]. HR of death 
within 28 days after the occurrence of MI for other 
variable and sub-variables in female was not 
statistically significant (Table 2). 
Discussion 
In overall, from 12815 patients with AMI that 
included in the study, 9307 (72.6%) were males, and 
sex ratio was 2.65, a higher proportion of men than 
women in the disease has been observed in other 
studies.25-28 The mean age at the time of occurrence 
of the disease in female, in average was 6.64 ± 3.04 
years higher than male. In other studies observed, 
that the average age in time of occurrence of the 
disease is higher in female than male.11,29,30 Short-
term (28 day) survival rate in the entire study period 
is 90.9%, for males 92.5% and for females 86.7%. 
Perhaps higher mortality during the first 28 days 
after the occurrence of MI in female resulting from 
to higher age, higher prevalence of diabetes, higher 
ratio of female with poor prognosis who survived to 
the hospital and due to the fact that aging is reduced 
pain perception and response to pain.20,29,31-37 Also, 
in recent years improvement in health care and the 
use of new technology and treatment can improve 
the survival rate. Of course, in Isfahan the Isfahan 
Healthy Heart Program (IHHP) in survival rates 
over time can be efficient.38 
As expected, in both sexes with increasing age-
adjusted HR of mortality is increased compared to 
baseline group, in a study that conducted by 
Stevenson et al. age was one of important 
determent factors in six-month survival rate in 
patients with AMI.39 However, The risk of death 
increased with rising age has been observed in other 
studies.40,41 
According to the ICD-10, MI divided into six 
categories. In this study, for the determent HR of 
mortality from AMI, considered group of patients 
who had the higher survival rate, as base group 
(acute subendocardial MI) and HR other groups, 
determined compared to this group. In two genders, 
acute, acute transmural MI of unspecified site have 
the highest HR compare basic group and after AMI, 
unspecified.  
In both sexes, acute transmural MI of anterior 
wall has higher HR compare acute transmural MI of 
inferior wall. Thus, in this study the anatomic 
location of MI was a significant predictor of 
survival. In a number of studies, prognosis of MI 
based location was different, So that the anterior 
surface infarction has a worse prognosis compared 
to inferior level.11,40,42 However, according to the 
method of data analysis in this study, difference in 
adjusted HR between various MI cannot caused by 
a variety of factors such as: gender, age, type of 
hospital, receive or did not receive streptokinase 
and type the first center to receive medical care. On 
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the other hand, because correct data about the 
differences among the mean interval between the 
occurrence of MI and go to health centers was not 
available, cannot image that this variable was 
ineffective, in the difference between the HRs 
among different types of MI. 
Streptokinase is the first fibrinolytic drug, 
which widely used in the word. This drug is 
derived from the group A streptococcus. Patients 
may have or produce antibodies against it 
microorganism or drug, respectively. If a patient 
has antibody agent this, antibody led to increased 
incidence of allergic reactions (severe type of 
anaphylaxis). In addition, the presence of 
antibodies against the drug can lead to 
streptokinase thrombolytic effectiveness reduced. 
In England, overall 82.0% of hospitals used 
streptokinase for treatment of patients that for the 
first time suffering from AMI and have medical 
conditions of receiving this drug.43 In this study 
not receiving streptokinase therapy in male, is not 
led to higher HR for death in the first 28 days after 
the occurrence of the disease, compared to the 
group receiving streptokinase (Table 1), but in 
female patients who received treatment 
(streptokinase therapy), compared to the group not 
receiving the drug has a lower HR (HR = 69%, 
95% CI: 56-84), that is statistically significant. 
In the present study, the HR of occurrence of 
death in both sexes in public hospitals is higher than 
private hospitals. Nevertheless, it should be note 
that the HR was statistically significant only in 
males. In a study that conducted with Chen et al.44 in 
American with name, “Do ‘America’s best 
hospitals’ perform better for AMI?” That 
conducted on 149, 177 patients with MI, the odds 
ratio (OR) for hospital mortality for the hospital 
with high rank was [relative risk (RR) = 76%, 95% 
CI: 69-84] against other hospitals. Survival was 
higher in patients admitted in this hospitals after 
entering variables such as disease severity and 
demographic characteristics of the patients, but 
after entering treatment quality indicators, adjusted 
OR was weaker and in terms of statistical not 
significant, so that its OR was equals (RR = 92%, 
95% CI: 82-1.04) which is not significant, in actually 
shows that higher use of drugs such as beta 
blockers and aspirin in high-rank hospitals in 
American, lead to lower mortality.44  
In calculation of the adjusted HR in this study, 
variables such as age, type of MI, receiving and not 
receiving the streptokinase, etc., that can be 
confounding role, considered. So cannot postulate 
that difference in survival rates due to differences in 
this variable, but we have not correct information 
about the differences between patients for receiving 
aspirin therapy. This article extracted from research 
project with code 84130 in 2011 in Isfahan 
Cardiovascular Research Institute. 
Limitations 
A difficulty of this study is a lack of complete, 
community-based case ascertainment, which 
contains through procedures for finding community 
fatal and nonfatal MI cases who are not admitted to 
the hospitals. Most important is the lack of data 
about out of hospital fatal cases, such as MI cases 
that managed at homes or in health centers. This 
figure might be unimportant since MI event is 
considering an emergency in Iran health care 
organization and total hospitals should admit such 
patients regardless of their insurance status. In 
Danish MONICA population, this number was 
measured to be not as much of as 0.1% of total MI 
cases in a year.45 Therefore, the missing these 
patients would not lead to sham decline in MI CFR. 
However, in this study due to lack of data about 
confounding variables such as diabetes, 
hypertension, smoking higher ratio of female with 
poor prognosis who survived to the hospital and 
due to the fact that aging is reduced pain perception 
and response to pain, are not included in the 
statistical model. Probably, perhaps higher mortality 
during the first 28 days after the occurrence of MI 
in female resulting from to higher age, a higher 
prevalence of diabetes, higher ratio of female with 
poor prognosis who survived to the hospital and 
due to the fact that aging is reduced pain perception 
and response to pain.20,29,31-37 Furthermore, in recent 
years improvement in health care and the use of 
new technology and treatment can improve the 
survival rate. Of course, in Isfahan the IHHP in 
survival rates over time can be efficient.38 
Conclusion 
The short-term survival rate in male was higher 
than female. In male age, anatomic location of MI 
and hospital status and in female streptokinase use 
and anatomic location of MI was the most 
important prognostic factors of survival in-patient 
with AMI in Iran. 
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